Analysis of Predisposing Factors for Hepatic Veno-Occlusive Disease after Treatment with Gemtuzumab Ozogamicin (Mylotargr, CMA-676).
Reviewer: William Levin, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: December 8, 2001
Presenter: Edward Stadtmauer
University of Pennsylvania Cancer Center
Hepatic veno-occlusive disease (VOD) occurs frequently after hematopoietic stem cell transplantation (HSCT) but is rarely seen with other forms of therapy.
Gemtuzumab Ozogamicin is a monoclonal anti-CD33 antibody that is used in the treatment of Acute Myeloid Leukemia.
Materials and Methods
Of 188 patients treated with gemtuzumab for relapsed AML in phase II studies, 4 developed hepatic VOD.
In the current study Investigators attempt to identify those factors that predispose patients to hepatic VOD.
A 2% incidence of hepatic VOD was seen in 188 patients treated with gemtuzumab for relapsed AML.
No correlation was found between the occurrence of VOD and age, gender, baseline bilirubin levels, prior chemotherapeutic regimens, or administration of concomitant medications.
Only prior autologous hematopoetic stem cell transplant was a risk factor for the development of hepatic VOD, but the correlation was a weak one (p=0.0384)
Efforts must continue to be made in order to identify factors associated with hepatic VOD.
Patients with a history of liver disease, elevated liver enzymes, and history of bone marrow transplant should be evaluated closely when considering them for gemtuzumab therapy.
This abstract illustrates the importance of clinical study in the evaluation of new medications.
The excitement over the emergence of new cancer therapies must be tempered by the continued monitoring for both acute and long term side-effects of these treatments.
Addition of Gemtuzumab Ozogamicin Ups Survival in AML
Apr 9, 2012 - For patients with untreated de novo acute myeloid leukemia, the addition of gemtuzumab ozogamicin to standard frontline chemotherapy improves event-free, overall, and relapse-free survival, without causing excessive toxicity, according to a phase 3 study published online April 5 in The Lancet.
Frequently Asked Questions
National Cancer Institute
I Wish You Knew
How cancer patients have changed my life
Blogs and Web Chats
OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.
Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!